AU2001248760A1 - Preventives/remedies for alzheimer's disease - Google Patents
Preventives/remedies for alzheimer's diseaseInfo
- Publication number
- AU2001248760A1 AU2001248760A1 AU2001248760A AU4876001A AU2001248760A1 AU 2001248760 A1 AU2001248760 A1 AU 2001248760A1 AU 2001248760 A AU2001248760 A AU 2001248760A AU 4876001 A AU4876001 A AU 4876001A AU 2001248760 A1 AU2001248760 A1 AU 2001248760A1
- Authority
- AU
- Australia
- Prior art keywords
- preventives
- remedies
- alzheimer
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000112046 | 2000-04-13 | ||
| JP2000-112046 | 2000-04-13 | ||
| PCT/JP2001/003189 WO2001078780A1 (en) | 2000-04-13 | 2001-04-13 | Preventives/remedies for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001248760A1 true AU2001248760A1 (en) | 2001-10-30 |
Family
ID=18624280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001248760A Abandoned AU2001248760A1 (en) | 2000-04-13 | 2001-04-13 | Preventives/remedies for alzheimer's disease |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20030134863A1 (en) |
| EP (1) | EP1393747A4 (en) |
| AU (1) | AU2001248760A1 (en) |
| CA (1) | CA2406832A1 (en) |
| WO (1) | WO2001078780A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040034039A1 (en) * | 2000-09-22 | 2004-02-19 | Yoshinori Nakano | Solid preparations |
| WO2002102401A1 (en) | 2001-04-30 | 2002-12-27 | Zentaris Gmbh | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
| DE10137174A1 (en) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Use of LHRH antagonists in non-castrating doses to improve T cell-mediated immunity |
| EP1479684A4 (en) * | 2002-01-30 | 2006-01-04 | Takeda Pharmaceutical | THIENOPYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE |
| AU2004207706B2 (en) | 2003-01-29 | 2010-03-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| GB0307777D0 (en) | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| TW201130854A (en) * | 2009-12-22 | 2011-09-16 | Bayer Schering Pharma Ag | Pyridinone derivatives and pharmaceutical compositions thereof |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| CN111574534B (en) * | 2020-05-25 | 2021-06-04 | 东莞市东阳光新药研发有限公司 | Phenyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048863A (en) * | 1994-04-19 | 2000-04-11 | Takeda Chemical Industries, Ltd. | Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use |
| TW449600B (en) * | 1994-04-19 | 2001-08-11 | Takeda Chemical Industries Ltd | Condensed-ring thiophene derivatives, their production and use |
| UY23948A1 (en) * | 1995-02-08 | 2001-10-25 | Takeda Chemical Industries Ltd | DERIVATIVES FROM THYPHENE CONDENSED RINGS, THEIR PRODUCTION AND USE. |
| AU2407997A (en) * | 1996-04-30 | 1997-11-19 | Takeda Chemical Industries Ltd. | Combined use of gnrh agonist and antagonist |
| TWI225863B (en) * | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| RU2233284C2 (en) * | 1999-03-24 | 2004-07-27 | Такеда Кемикал Индастриз, Лтд. | Thienopyrimidine derivatives, method for their preparing, pharmaceutical composition and method for antagonization of gonadotropin-releasing hormone |
-
2001
- 2001-04-13 EP EP01921830A patent/EP1393747A4/en not_active Withdrawn
- 2001-04-13 AU AU2001248760A patent/AU2001248760A1/en not_active Abandoned
- 2001-04-13 CA CA002406832A patent/CA2406832A1/en not_active Abandoned
- 2001-04-13 WO PCT/JP2001/003189 patent/WO2001078780A1/en not_active Ceased
- 2001-04-13 US US10/240,949 patent/US20030134863A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2406832A1 (en) | 2002-10-10 |
| US20030134863A1 (en) | 2003-07-17 |
| EP1393747A1 (en) | 2004-03-03 |
| WO2001078780A1 (en) | 2001-10-25 |
| EP1393747A4 (en) | 2004-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001233299A1 (en) | Methods for treating alzheimer's disease | |
| AU2001273132A1 (en) | Compounds to treat alzheimer's disease | |
| AU2002219824A1 (en) | Compositions and methods for diagnosing alzheimer's disease | |
| AU2001278084A1 (en) | Model for alzheimer's disease and other neurodegenerative diseases | |
| AU1407399A (en) | Treatment for alzheimer's disease | |
| AU2610901A (en) | Predictive diagnostic for alzheimer's disease | |
| AU2001286221A1 (en) | Remedies for ischemic diseases | |
| AU2639299A (en) | Remedies/preventives for parkinson's disease | |
| AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| AU2001281034A1 (en) | Alzheimer's tester | |
| AU2001236592A1 (en) | Methods for diagnosis of alzheimer's disease | |
| AU2000279614A1 (en) | Remedies for endothelin-induced diseases | |
| AU2001248760A1 (en) | Preventives/remedies for alzheimer's disease | |
| AU2002232419A1 (en) | Clinician's assistant system | |
| AU2001241162A1 (en) | Remedies for allergic diseases | |
| AU2001236006A1 (en) | Preventives/remedies for kidney diseases | |
| AU1405899A (en) | Treatment for alzheimer's disease | |
| AU2002224022A1 (en) | Preventives or remedies for endoplasmic reticulum stress-associated diseases | |
| AU2001267826A1 (en) | Remedies for alzheimer's disease | |
| AU2002242348A1 (en) | Process for obtaining 3'-epilutein | |
| AU2001271026A1 (en) | Remedies for bone diseases | |
| AU2002232401A1 (en) | Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease | |
| AU2001228863A1 (en) | Remedies for ophthalmic diseases | |
| AU2001230573A1 (en) | Remedies for behcet's disease | |
| AU2001246518A1 (en) | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |